[1] Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D. An official American Thoracic Society/European Respiratory Society statement: Update
of the international multidisciplinary classification of the idiopathic interstitial
pneumonias. Am J Respir Crit Care Med 2013; 188: 733-748.
[2] Hu Y, Wang LS, Wei YR, et al. Clinical characteristics of connective tissue disease-associated interstitial
lung disease in 1044 Chinese patients. Chest 2016; 149(1): 201-208.
[3] Cohen JT, Bach KK, Postma GN, et al. Clinical manifestations of laryngopharyngeal
reflux. Ear Nose Throat J 2002; 81(9 Suppl 2): 19-23.
[4] Hom C, Vaezi MF. Extra-esophageal manifestations of gastroesophageal reflux disease:
diagnosis and treatment. Drugs 2013; 73(12): 1281-1295.
[5] Lai KF, Chen RC, Lin JT, et al. A prospective, multicenter survey on causes of
chronic cough in China. Chest 2013; 143(3): 613-620.
[8] Lee JS, Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ, King TE Jr, Collard HR. Gastroesophageal reflux therapy is associated with longer survival in patients with
idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184:1390–1394.
[9] Raghu G, Freudenberger TD, Yang S, Curtis JR, Spada C, Hayes J, Sillery JK, Pope CE II, Pellegrini CA. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary
fibrosis. Eur Respir J 2006;27:136–142.
[10] Lee JS, Collard HR, Anstrom KJ, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis:
an analysis of data from three randomised controlled trials. Lancet Respir Med 2013; 1(5):369-376.
[11] Koufman JA. Laryngopharyngeal reflux 2002: a new paradigm of airway disease.
Ear Nose Throat J 2002; 81(9 Suppl 2): 2-6.
[18] Su Y, Gu H, Weng D, et al. Association of serum levels of laminin, type IV collagen, procollagen III N-terminal peptide, and hyaluronic acid with the progression of interstitial lung disease. Medicine 2017; 96(18): e6617.
[19] van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA Jr, Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka O, Muller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH, Csuka ME, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski S, Silver RM, Simms RW, Varga J, Pope JE. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative
initiative. Arthritis Rheum 2013; 65: 2737-2747.
[21] Sun G, Muddana S, Slaughter JC, et al. A new pH catheter forlaryngopharyngeal reflux:
normal values. Laryngoscope 2009; 119(8): 1639-1643.
[22] Chung KF. Measurement of cough. Respir Physiol Neurobiol 2006; 152(3): 329-339.
[24] Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, Lee JS, Leslie KO, Lynch DA, Matteson EL, Mosca M, Noth I, Richeldi L, Strek ME, Swigris JJ, Wells AU, West SG, Collard HR, Cottin V. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 2015; 46: 976-987.
[25] Ford CN. Evaluation and management of laryngopharyngeal reflux. JAMA 2005; 294(12):
1534-1540.
[26] Yuksel ES, Vaezi MF. Therapeutic Strategies for Laryngeal Manifestations of Gastroesophageal
Reflux Disease. J Clin Gastroenterol 2013; 47(3): 195-204.
[27] Wiener GJ, Tsukashima R, Kelly C, et al. Oropharyngeal pHmonitoring for the detection
of liquid and aerosolizedsupraesophageal gastric reflux. J Voice 2009; 23(4): 498-504.
[28] Vailati C, Mazzoleni G, Bondi S, et al. Oropharyngeal pHmonitoring for laryngopharyngeal
reflux: is it a reliable test beforetherapy? J Voice 2013; 27(1): 84-89.
[30] Park W, Hicks DM, Khandwala F, et al. Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose
of proton-pump inhibitor therapy and pretherapy predictors of response. Laryngoscope 2005; 115(7): 1230-1238.
[31] Sato K. Laryngopharyngeal reflux disease with nocturnal gastric acid breakthrough while on proton pump inhibitor
therapy. Eur Arch Otorhinolaryngol 2006; 263(12): 1121-1126.
[32] Glicksman JT, Mick PT, Fung K, et al. Prokinetic agents and laryngopharyngeal reflux disease: Prokinetic agents
and laryngopharyngeal reflux disease: a systematic review. Laryngoscope 2014; 124(10): 2375-2379.